In November 2025, Northwestern University agreed to pay $2,303,749 to the federal government after self-disclosing to the Department of Health and Human Services Office of Inspector General (HHS-OIG) that a former researcher at its Feinberg School of Medicine had falsified data used in NIH grant applications and reports. Retraction Watch reported the settlement on January 14, 2026. The important detail for research administrators: this was resolved as a Civil Monetary Penalties Law (CMPL) settlement with HHS-OIG, not a Department of Justice False Claims Act (FCA) case — a distinction that matters both legally and for what it signals about the value of self-disclosure.
For the general legal framework — elements of an FCA claim, qui tam mechanics, and typical penalty exposure — see CASRAI’s guide, The False Claims Act in Research Grant Compliance. This piece covers what actually happened in the Northwestern matter and, separately, clears up a real source of confusion: an unrelated, older Northwestern settlement is sometimes cited alongside this one under a similar-sounding headline.
What Northwestern disclosed and settled
According to HHS-OIG’s enforcement summary, Northwestern self-disclosed that a former researcher falsified research funded by NIH award R01GM081603, and that the falsified research was then cited in grant applications, progress reports, and other submissions supporting two additional NIH awards, R01HL114763 and R01HL141459. The three grants together totaled roughly $5 million in NIH funding, with about $3.5 million of that tied specifically to Northwestern. OIG’s public enforcement notice frames the resolved conduct as a violation of the Civil Monetary Penalties Law arising from false claims tied to falsified research — the $2,303,749 figure is the CMPL settlement amount, reached without DOJ litigation or a qui tam suit.
The researcher named across the three awards as principal investigator, per Retraction Watch’s reporting, is Jing Liu, who worked at Northwestern’s Feinberg School of Medicine from approximately 2008 to 2018 and now works at the University of Illinois Cancer Center. HHS-OIG’s own notice does not name the researcher; the identification comes from Retraction Watch’s independent reporting on the underlying case.
The underlying research conduct
The falsification was tied to a 2013 Nature Immunology paper on the gene regulator Miz1 and its role in inflammation, which has since been retracted. Retraction Watch reported that seven of the paper’s sixteen co-authors disagreed with the retraction — a common pattern in multi-author falsification cases, where responsibility for a single manipulated figure or dataset does not extend evenly across every listed author. See CASRAI’s dictionary entries on falsification and fabrication, and the comparison page Falsification vs. Fabrication: What’s the Difference?, for how these terms are defined and distinguished under the U.S. federal research-misconduct policy that HHS’ Office of Research Integrity (ORI) applies in parallel to matters like this one.
Why this is a CMPL case, not an FCA settlement
This kind of grant-fraud conduct is often described informally as a “False Claims Act” matter, but that is not the legal mechanism HHS-OIG actually used here. The FCA is enforced through DOJ, typically via a government-initiated suit or a qui tam action brought by a private whistleblower under seal, and it carries treble damages and per-claim penalties. The Civil Monetary Penalties Law is a separate HHS-OIG administrative enforcement authority, and OIG’s own published notice for this matter cites CMPL, not the FCA, as the basis for the $2.3 million figure.
The practical reason CMPL applied here rather than FCA litigation is Northwestern’s self-disclosure. When an institution self-reports research misconduct with a false-claims dimension to HHS-OIG before the government otherwise learns of it, OIG has discretion to resolve the matter administratively — generally faster, less costly, and less publicly adversarial than a DOJ-litigated FCA settlement. Compare CASRAI’s coverage of Dana-Farber’s $15 million FCA settlement over image manipulation, which was resolved through DOJ litigation after allegations surfaced through public, third-party image-integrity critique rather than institutional self-disclosure. The gap between a roughly $2.3 million CMPL resolution and a $15 million FCA settlement is a real, current illustration of the incentive self-disclosure protocols are built around.
Not the same case as Northwestern’s earlier FCA settlement
A separate, unrelated Northwestern matter is easy to conflate with this one because it involves a similar dollar figure and the same school. In a 2013 settlement, Northwestern paid the United States nearly $3 million (reported as roughly $2.93 million) to resolve False Claims Act allegations that a different Feinberg School of Medicine researcher, Dr. Bennett, billed federal cancer-research grants for personal expenses — family trips, meals, hotels, and consulting fees paid to unqualified friends and relatives. That case originated as a qui tam suit filed under seal in 2009 by a former Feinberg purchasing coordinator, who received roughly $498,100 of the settlement as the whistleblower’s share, and it was an actual DOJ False Claims Act settlement, not a CMPL matter.
The two cases share an institution and a school but nothing else: different researchers, more than a decade apart, different underlying conduct (billing and expense fraud in 2013 versus falsified research data referenced across grant submissions in the 2025-2026 matter), and different legal mechanisms (FCA qui tam litigation versus CMPL self-disclosure). Anyone citing “Northwestern’s False Claims Act settlement” without a date or dollar figure attached should be read carefully — both are real, and they are not the same matter.
What this means for research administrators
- Self-disclosure has a documented cost difference. Set against the same general fact pattern — falsified or manipulated research findings referenced in NIH grant submissions — the self-disclosed CMPL route produced a settlement roughly one-sixth the size of the litigated FCA settlement Dana-Farber reached over a comparable underlying problem.
- CMPL and FCA are not interchangeable. Grants and compliance offices tracking exposure from a data-integrity finding should identify which statute a given resolution falls under before citing dollar figures in institutional risk assessments — the legal theory, process, and public visibility differ substantially.
- A single falsified dataset can taint multiple grants. The Northwestern case shows how falsified data generated under one award (R01GM081603) became a compliance problem for two additional, later awards (R01HL114763, R01HL141459) once it was cited in their supporting submissions — a reminder that data-integrity review needs to trace citation and reuse across a researcher’s full award portfolio, not just the grant where fabrication originated.
For background on how research-misconduct findings escalate into formal proceedings, see CASRAI’s guides How a Research Misconduct Investigation Actually Works and The Consequences of Research Misconduct: Career, Funding, and Legal Outcomes. For FCA exposure specific to clinical billing rather than grant data, see False Claims Act Liability in Clinical Trial Billing.
Sources
- HHS Office of Inspector General, enforcement notice: “Northwestern University Agreed To Pay $2.3 Million For Allegedly Violating The Civil Monetary Penalties Law By Submitting False Claims To NIH-Funded Grants Involving Falsified Research” (oig.hhs.gov)
- Retraction Watch, “Northwestern to pay $2.3 million for falsified research in NIH grants,” January 14, 2026 (retractionwatch.com)
- U.S. Department of Justice, U.S. Attorney’s Office, Northern District of Illinois, “Northwestern University To Pay Nearly $3 Million To The United States To Settle Cancer Research Grant Fraud Claims” (justice.gov)
